Japanese journal of clinical oncology最新文献

{"title":"An inadequate number of first-line chemotherapy cycles provides poor survival outcomes in patients with metastatic urothelial carcinoma receiving avelumab maintenance: results from the chu-shikoku Japan urological consortium.","authors":"Satoshi Katayama, Takehiro Iwata, Shingo Nishimura, Kensuke Bekku, Keita Kobayashi, Nakanori Fujii, Kenichi Nishimura, Noriyoshi Miura, Yoichiro Tohi, Takuma Kato, Shinkuro Yamamoto, Hideo Fukuhara, Atsushi Takamoto, Ryutaro Shimizu, Shuichi Morizane, Yutaro Sasaki, Kei Daizumoto, Taichi Nagami, Koichiro Wada, Motoo Araki","doi":"10.1093/jjco/hyaf163","DOIUrl":"https://doi.org/10.1093/jjco/hyaf163","url":null,"abstract":"<p><strong>Purpose: </strong>Despite 4-6 cycles of first-line chemotherapy being recommended before the initiation of avelumab maintenance treatment, a non-negligible number of patients received <4 cycles of first-line chemotherapy due to adverse events or pre-existing comorbidities. We assessed the prognostic impact of the number of first-line chemotherapy cycles in patients with metastatic urothelial carcinoma (mUC) treated with avelumab maintenance.</p><p><strong>Methods: </strong>In this multi-institutional study, data were collected from patients with mUC who received avelumab maintenance treatment following first-line chemotherapy. Patients were divided into those who received <4 cycles versus ≥4 cycles of first-line chemotherapy. Kaplan-Meier curves and Cox regression analysis were used to assess the association of chemotherapy cycle numbers with overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>Of 91 patients included in this analysis, 17 (19%) underwent <4 cycles of chemotherapy. Patients with <4 cycles of first-line chemotherapy were less likely to receive carboplatin-containing chemotherapy compared with their counterparts (6% versus 39%). On multivariable Cox regression analyses adjusted for the effects of confounding factors, receiving <4 cycles of chemotherapy was significantly associated with worse OS and CSS (HR 2.85; P = .006 and HR 3.18; P = .005, respectively), which was confirmed by subgroup analysis focusing on patients with 1-6 cycles of chemotherapy. Cisplatin-based chemotherapy use was associated with better OS over carboplatin-based chemotherapy (HR 0.41; P = .033).</p><p><strong>Conclusions: </strong>An inadequate number of first-line chemotherapy cycles was associated with poor survival outcomes. Four or more cycles of first-line platinum-based chemotherapy may be beneficial to ensure the efficacy of avelumab maintenance treatment in patients with mUC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case report.","authors":"Miho Fujiwara, Kiichiro Ninomiya, Emi Chikuie, Yoshihiro Saeki, Kazuaki Tanabe, Go Makimoto, Shigeru Horiguchi, Shuta Tomida, Daisuke Ennishi, Noboru Yamamoto, Shinichi Toyooka, Yoshinobu Maeda, Eiki Ichihara","doi":"10.1093/jjco/hyaf162","DOIUrl":"https://doi.org/10.1093/jjco/hyaf162","url":null,"abstract":"<p><p>Fibroblast growth factor receptor 2 (FGFR2) gene fusions are detected in 10%-16% of cholangiocarcinomas but are rarely detected in other solid tumours. Herein, we report the case of a 59-year-old woman with stage IVB gastric cancer (UICC 8th edition) characterized by FGFR2-TRIM44 fusion and FGFR2 amplification. Her tumour progressed despite multiple lines of standard chemotherapy. Plasma ctDNA analysis revealed these alterations, and pemigatinib was recommended by an expert panel. Treatment led to a remarkable clinical and radiological response, and she remained on pemigatinib with stable symptoms for 5 months. According to the C-CAT database, FGFR2 amplification was identified in 4.9%, while FGFR2 fusions were identified in only 0.26% of 3116 oesophagogastric adenocarcinomas, with FGFR2-TRIM44 fusions detected in just 0.064%, including our case. Targeted therapies based on genomic information are limited in the treatment of advanced gastric cancer. Thus, this case suggests that pemigatinib may represent a promising targeted therapy option for patients with advanced gastric cancer harbouring FGFR2 alterations.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hand grip strength and peak expiratory flow rate as predictors of overall survival after esophagectomy for esophageal cancer.","authors":"Shota Sawai, Shinsuke Sato, Eiji Nakatani, Philip Hawke, Takuma Mochizuki, Masato Nishida, Hiroshi Ogiso, Masaya Watanabe","doi":"10.1093/jjco/hyaf164","DOIUrl":"https://doi.org/10.1093/jjco/hyaf164","url":null,"abstract":"<p><strong>Objective: </strong>Esophageal cancer is one of the most lethal cancers worldwide. Previous studies have shown that reduced skeletal and respiratory muscle strength is correlated with increased postoperative complications. This study investigated the relationship between hand grip strength (HGS) and respiratory muscle strength assessed as peak expiratory flow (PEF) rate. We also examined the association of these factors with long-term prognosis in patients who had undergone radical esophagectomy for esophageal cancer.</p><p><strong>Methods: </strong>We reviewed 392 patients who underwent radical subtotal esophagectomy from 2007 to 2023. HGS and PEF rate were measured preoperatively. Data analysis included univariable and multivariable Cox regression to identify prognostic factors for overall survival (OS).</p><p><strong>Results: </strong>During a median follow-up of 36 months, 171 patients died, with 68.1% of deaths attributable to the primary disease. Because a weak correlation was observed between HGS and PEF rate (r = 0.353), separate multivariate analyses were performed for each factor to investigate their relationship to prognosis. Multivariable analysis identified PEF rate as an independent prognostic factor for OS (HR 0.991, 95% CI 0.984-0.999; P = .028), along with clinical stage (HR 1.345, 95% CI 1.188-1.521; P < .001), age (HR 1.026, 95% CI 1.007-1.046; P = .008), and surgical approach (open vs. minimally invasive; HR 0.674, 95% CI 0.490-0.928; P = .015). HGS was also identified as an independent prognostic factor for OS (HR 0.974, 95% CI 0.955-0.994; P = .012) along with clinical stage (HR 1.321, 95% CI 1.168-1.495; P < .001).</p><p><strong>Conclusions: </strong>HGS and PEF rate are independent predictors of OS after esophagectomy.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium.","authors":"Taizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, Sho Kakumae, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Moritoshi Sakamoto, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Kyosuke Nishio, Yuki Yoshikawa, Atsushi Ichihashi, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Kazutoshi Fujita, Haruhito Azuma, Takahiro Kimura, Kazumasa Komura","doi":"10.1093/jjco/hyaf161","DOIUrl":"https://doi.org/10.1093/jjco/hyaf161","url":null,"abstract":"<p><strong>Background: </strong>Androgen receptor signaling inhibitors (ARSIs) have become the standard treatment for metastatic castration-sensitive prostate cancer (mCSPC). While visceral metastases, including lung metastases (LMs), are considered poor prognostic factors, their impact on clinical outcomes in mCSPC remains unclear. This study aimed to evaluate the prognostic significance of LM in mCSPC patients treated with ARSI-based doublet therapy.</p><p><strong>Methods: </strong>This retrospective study analyzed a multi-institutional cohort of 453 mCSPC patients treated with ARSIa-based doublet therapy.</p><p><strong>Results: </strong>The median overall survival (OS) and time to castration resistance (TTCR) were 80 and 41 months, respectively, with a median follow-up of 20 months. The total cohort included 117 patients (25.8%) with LM and 336 patients (74.2%) without LM. LATITUDE high-risk and CHAARTED high-volume criteria classified 380 patients (83.9%) and 356 patients (78.6%), respectively. Although not statistically significant, OS and TTCR showed a trend toward better outcomes in the LM group compared to the non-LM group in LATITUDE high-risk (n = 380: P = .097 for OS and P = .104 for TTCR) and CHAARTED high-volume (n = 356: P = .064 for OS and P = .086 for TTCR). In the propensity score matching cohort (n = 218 and n = 206 for LATITUDE and CHAARTED criteria, respectively), OS and TTCR remained comparable between the LM and non-LM groups.</p><p><strong>Conclusions: </strong>LM does not appear to be related to OS or TTCR in mCSPC patients treated with ARSI-based doublet therapy, indicating that its prognostic value may need to be reevaluated.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma.","authors":"Yuko Shirouchi, Nobuhiko Yamauchi, Dai Maruyama","doi":"10.1093/jjco/hyaf158","DOIUrl":"https://doi.org/10.1093/jjco/hyaf158","url":null,"abstract":"<p><p>Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of lymphomas with a generally poor prognosis. With recent advances in our understanding of the cellular origins and genomic profiles of PTCL, lymphomas of follicular helper T-cell (TFH) origins with distinct markers and gene mutation profiles are categorized as a single entity, nodal TFH lymphomas-angioimmunoblastic type, follicular type, and not otherwise specified, in the fifth edition of the WHO classification. The standard treatment for PTCL has been CHOP or CHOP-like regimens for decades. The ECHELON-2 trial marked a significant advance in the treatment of PTCL by demonstrating significantly longer survival with BV-CHP than with CHOP for CD30-positive PTCL, establishing BV-CHP as the standard of care for this group of patients. However, attempts to integrate other novel agents into CHOP have largely been unsuccessful, primarily due to increased toxicity, and, thus, CHOP remains the standard treatment for CD30-negative PTCL. Upfront autologous stem cell transplantation is currently controversial, and ongoing randomized controlled trials are expected to clarify its role. With advances in our understanding of the molecular and genetic characteristics of PTCL and potential predictive biomarkers, the future development of treatment will focus on more stratified approaches, and ongoing trials are expected to provide further insights into optimizing these treatment strategies.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized risk stratification for postmastectomy radiation therapy in node-positive breast cancer: moving beyond universal guidelines.","authors":"Akimitsu Yamada, Kazutaka Narui, Takashi Ishikawa, Itaru Endo","doi":"10.1093/jjco/hyaf153","DOIUrl":"https://doi.org/10.1093/jjco/hyaf153","url":null,"abstract":"<p><p>Postmastectomy radiation Therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality in patients with ≥4 positive lymph nodes. However, evidence supporting PMRT in patients with 1-3 positive nodes remains limited. While the 2014 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated benefit in this population, the constituent trials preceded current standard practices including sentinel lymph node biopsy, contemporary systemic therapies, and modern radiation therapy techniques. This analysis examines the applicability of EBCTCG findings to current clinical practice. Historical trials reported elevated LRR rates, potentially attributable to inadequate axillary staging and suboptimal systemic therapy regimens such as cyclophosphamide, methotrexate, and fluorouracil. Contemporary studies demonstrate substantially lower LRR rates in comparable patients managed without PMRT, particularly those with favorable tumor characteristics. Current adjuvant therapies-including anthracyclines, taxanes, trastuzumab, endocrine agents, and targeted therapies such as abemaciclib and olaparib-have markedly reduced recurrence risk. Retrospective analyses yield conflicting results regarding PMRT efficacy, while randomized trials (SUPREMO, TAILOR RT) seek to refine treatment indications. Contemporary practice should not universally recommend PMRT for intermediate-risk patients (1-3 nodes); instead, individualized risk assessment is warranted. The role of PMRT remains undefined in patients without axillary lymph node dissection or those achieving pathologic complete response following neoadjuvant therapy. Clinical decision-making must consider treatment benefits relative to potential late toxicities and reconstructive complications. Personalized, evidence-based approaches informed by emerging trial data represent the optimal strategy for patient management.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis-based treatment strategies for brain metastases from non-small cell cancer.","authors":"Toshihiko Iuchi, Masato Shingyoji, Hironori Ashinuma, Satoko Mizuno, Yuzo Hasegawa, Taiki Setoguchi, Junji Hosono, Tsukasa Sakaida","doi":"10.1093/jjco/hyaf155","DOIUrl":"https://doi.org/10.1093/jjco/hyaf155","url":null,"abstract":"<p><p>More than half of brain metastases (BMs) in patients with non-small cell lung cancer are diagnosed at the time of lung cancer diagnosis and are therefore potentially amenable to systemic treatment. Before the introduction of molecular targeting therapy, medical treatment was thought to be ineffective owing to the presence of the blood-brain barrier (BBB). However, the molecular activities of cancer cells in the central nervous system affect the brain microenvironment, changing the function of the BBB and blood-cerebrospinal fluid barrier, allowing drug delivery. In non-small cell lung cancer with driver gene mutations, BMs respond rapidly to molecular targeted drugs. Although the immune response is attenuated within BMs, it varies according to cancer type. In addition, the changes in immune response after immune checkpoint inhibitor administration vary from patient to patient. In treating BMs, which develop in the unique environment of the brain, it is particularly important to understand these pathologies and develop pathogenesis-based treatment strategies. Although drug therapy is effective against BMs, it is not curative, as BMs will eventually acquire resistance. In the era of molecular targeted agents, it is important to determine the most appropriate combination of treatments for each individual patient, taking into account the effectiveness of conventional local treatments and drug therapy, the presence of side effects, and the timing of their onset.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan.","authors":"Terufumi Kato, Tatsuya Ogura, Masashi Sato, Risa Kojima, Bingbing Song, Eisuke Horii, Kazuhiko Nakagawa","doi":"10.1093/jjco/hyaf099","DOIUrl":"10.1093/jjco/hyaf099","url":null,"abstract":"<p><strong>Objective: </strong>Tepotinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The objective of this post-marketing surveillance (PMS) was to assess the safety and effectiveness of tepotinib in general clinical practice in Japan.</p><p><strong>Methods: </strong>This multicenter, non-interventional PMS included patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations who received at least one dose of tepotinib. The primary endpoint was the incidence of adverse drug reactions (ADRs) identified as safety specifications (SS) for tepotinib according to the Japanese Risk Management Plan (ADRs of SS); i.e. interstitial lung disease (ILD), fluid retention, hepatic function disorder, renal impairment, and QT interval prolongation (classified by preferred term). The secondary endpoints were ADRs of SS in patient subgroups and the effectiveness of tepotinib in clinical practice. In total, 147 patients were included (median age 72.0 years).</p><p><strong>Results: </strong>The incidence of ILD, fluid retention, hepatic function disorder, and renal impairment was 7.5%, 47.6%, 13.6%, and 36.1%, respectively; incidence of grade ≥3 ADRs of SS were 3.4%, 9.5%, 4.8%, and 2.7%, respectively. No instances of QT interval prolongation occurred. Four patients (2.7%) died due to ILD. The objective response rate was 51.0% [95% confidence interval (CI) 42.7, 59.3] and disease control rate was 77.6% (95% CI 69.9, 84.0).</p><p><strong>Conclusions: </strong>Tepotinib was generally well tolerated and effective in patients with NSCLC and METex14 skipping alterations in general clinical practice in Japan; no new safety issues or concerns were identified.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1152-1161"},"PeriodicalIF":2.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suicide risk among individuals diagnosed with cancer during versus before the COVID-19 pandemic: a nationwide population-based study.","authors":"Ken Kurisu, Maiko Fujimori, Saki Harashima, Tatsuo Akechi, Kazuhiro Yoshiuchi, Yosuke Uchitomi","doi":"10.1093/jjco/hyaf110","DOIUrl":"10.1093/jjco/hyaf110","url":null,"abstract":"<p><p>This study aimed to assess suicide risk among individuals diagnosed with cancer shortly after the onset of the COVID-19 pandemic compared to those diagnosed earlier. Data were obtained from the National Cancer Registry in Japan, which included 4 711 540 individuals diagnosed between January 2016 and June 2020. Standardized mortality ratios (SMRs) for suicide within 6 months of diagnosis were quantified using the general population as a reference. Those diagnosed between April and June 2020 had an SMR of 3.93 (95% confidence interval: 3.10-4.91), higher than those diagnosed in earlier periods. Additionally, multivariate Poisson regression showed an adjusted relative risk of 1.30 (95% confidence interval: 1.03-1.63) for individuals diagnosed during the pandemic compared to earlier periods. These findings suggest that individuals diagnosed with cancer shortly after the onset of the COVID-19 pandemic had a higher suicide risk than those diagnosed earlier.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1194-1197"},"PeriodicalIF":2.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinoma.","authors":"Yoshiaki Kurokawa, Taketo Kawai, Satoru Taguchi, Kazuki Honda, Kazuki Maki, Yoshiki Ambe, Naoki Saegusa, Masahiro Yamamoto, Yuumi Tokura, Kazuki Yanagida, Kazuki Takei, Hazuki Inoue, Takehiro Tanaka, Katsuhiko Nara, Tomoyuki Kaneko, Yoichi Fujii, Jimpei Miyakawa, Jun Kamei, Shigenori Kakutani, Aya Niimi, Daisuke Yamada, Yuta Yamada, Tappei Takada, Tohru Nakagawa, Haruki Kume","doi":"10.1093/jjco/hyaf105","DOIUrl":"10.1093/jjco/hyaf105","url":null,"abstract":"<p><strong>Background: </strong>Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) therapy is expected to provide superior therapeutic efficacy compared to gemcitabine and cisplatin therapy as systemic chemotherapy for urothelial carcinoma. However, its high incidence of adverse events raises concerns about tolerability, particularly in older patients. This study evaluated the utility of the Geriatric 8 (G8) screening tool in patients undergoing dd-MVAC therapy and assessed its association with treatment progress.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 65 patients with urothelial carcinoma who received dd-MVAC therapy between August 2018 and May 2023, with the goal of completing six treatment cycles. The G8 score was evaluated before treatment initiation, and its association with treatment completion and adverse events was examined.</p><p><strong>Results: </strong>The median age of patients was 71 years (range, 43-84 years), with 65% male and 35% female. The median pretreatment G8 score was 13 (range, 7-17). Patients with a G8 score ≥14 demonstrated a significantly higher six-cycle treatment completion rate than those with a G8 score <14 (87% vs. 60%, P = 0.026). The incidence of adverse events did not differ between the groups. Furthermore, among various clinicopathological factors, the G8 score was identified as an independent predictor of six-cycle treatment completion (odds ratio: 0.17, P = 0.021), along with Eastern Cooperative Oncology Group Performance Status.</p><p><strong>Conclusion: </strong>Pretreatment G8 scores were associated with the treatment completion rates of dd-MVAC therapy.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1177-1183"},"PeriodicalIF":2.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}